Key result
Psoriasis is linked to up to ~50% higher CVD risk, correlating with skin severity.
Why the study?
Patients with psoriasis have increased cardiovascular risk linked to inflammatory pathways, but randomized trials on treatment effects on CV risk remain inconclusive.
Answers are grounded in this paper and cite their sources.
Psoriasis is associated with a significantly increased risk of cardiovascular disease, supporting guideline recommendations to incorporate it into cardiovascular risk prediction and prevention strategies.
Psoriasis is a chronic inflammatory skin disease that affects 2% to 3% of the U.S. population. The immune response in psoriasis includes enhanced activation of T cells and myeloid cells, platelet activation, and up-regulation of interferons, tumor necrosis factor-α, and interleukins (ILs) IL-23, IL-17, and IL-6, which are linked to vascular inflammation and atherosclerosis development. Patients with psoriasis are up to 50% more likely to develop cardiovascular disease (CV) disease, and this CV risk increases with skin severity. Major society guidelines now advocate incorporating a psoriasis diagnosis into CV risk prediction and prevention strategies. Although registry data suggest treatment targeting psoriasis skin disease reduces vascular inflammation and coronary plaque burden, and may reduce CV risk, randomized placebo-controlled trials are inconclusive to date. Further studies are required to define traditional CV risk factor goals, the optimal role of lipid-lowering and antiplatelet therapy, and targeted psoriasis therapies on CV risk.
No takes yet. Share an insight, caveat, or question.
Garshick et al. (2021) conducted a review in Psoriasis. Psoriasis was evaluated on Cardiovascular disease. Patients with psoriasis have up to a 50% increased risk of developing cardiovascular disease, which correlates with skin severity, though trials on targeted therapies remain inconclusive.
Synapse has enriched 10 related papers. Consider them for comparative context: